Dyne Therapeutics Inc

The asset has decisively broken key horizontal support, shifting the medium-term bias bearish under a Stage 3 distribution outlook. Near-term price is oversold and extended below all major EMAs, so optimal execution should be deferred until a relief rally back into the prior support zone around 21.46–19.88, where resistance is likely to cap supply. While the long-term trend remains structurally up, near-term momentum favors selective trimming into rallies.

• ↑High 13F ownership signals strong hedge fund confidence
• ↑Positive momentum with share price up on recent trends
• ↓Earnings yield at –2.15% and profitability score –2.42 signal poor returns